GSK has terminated its $2.2 billion neuroscience collaboration with Alector after two clinical failures in Alzheimer’s and frontotemporal dementia programs.
The partnership, signed in 2021, included a $700 million upfront payment from GSK to Alector and up to $1.5 billion in potential milestones, most of which will now go unpaid.
Both lead monoclonal antibodies—latozinemab and nivisnebart—failed in trials, prompting GSK to cut its losses and walking away from the deal after a 180‑day notice period that ends January 2, 2027.
Sources:
GSK cuts losses on $700M upfront Alzheimer's collab with Alector
Alector and GSK partnership to end after dementia, Alzheimer's drug failures
GSK ends Alector alliance as both lead assets fail - EMJ GOLD
UK housing market downturn eases but sentiment remains ‘fragile', surveyors say
Alector dementia drug, partnered with GSK, fails in key study
GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints
GSK Juggles Alzheimer's Setback And Leadership Shift With Product Progress
GSK and Alector announce global collaboration in immuno ...
GSK, Alector Halt Alzheimer's Trial Over Futility - LinkedIn
Alector ditches GSK-partnered dementia drug and cuts staff
GSK cuts losses on $700M upfront Alzheimer's collab with Alector ...
GSK invests $700 million in Alector
GSK Ends Alector Alzheimer’s Bet And Refocuses On ADC Oncology Potential